Cognia Announces SBIR Award for Protein Catabolism Database System

Award Will Fund Continued System Design, Enhancement and Population



Apr 20, 2001, 01:00 ET from Cognia Corporation

    NEW YORK, April 20 /PRNewswire Interactive News Release/ -- Cognia
 Corporation announced today the award of a one-year SBIR-Phase I grant from
 the National Institutes for General Medical Sciences (NIGMS) to create a
 comprehensive database resource on protein catabolism. The award will fund the
 initial implementation of a broadly designed system to allow access to
 relevant primary data and annotated information. The initial focus of the
 system will be the highly-regulated ubiquitin-proteasome pathways, which are
 of fundamental importance for regulating intracellular protein levels.
     This database will have direct relevance to Cognia's existing
 pharmaceutical and biotechnology customers as perturbations in the system lead
 to many types of disease, including various cancers, neurological disorders,
 and inflammatory diseases. Protein catabolism is becoming a major focus for
 drug targeting and lead identification, in addition to being of prime
 importance in the exploration of pharmaceutical side effects. "Though not
 originally described by the central dogma of biology, protein turnover has
 emerged as equal in importance to transcription," says Cognia President and
 CEO, David M. Rubin, Ph.D. "Cognia is building a system to provide biological
 context for the coming wave of proteomics data as well as standard RNA-based
 microarray data."
     Cognia is also pleased to announce that Christopher N. Larsen, Ph.D, has
 joined the team to manage the protein catabolism database product. Dr. Larsen
 has advanced the protein catabolism field through over ten years of research.
 At Emory University, he helped define the ubiquitin C-terminal hydrolase
 family, including gene members, tissue and hydrolytic specificities, and
 crystal structures. At Harvard Medical School, he elucidated subunit
 structure-function relationships of the massive eukaryotic 26S proteasome.
 Dr. Larsen's work is published in many peer-reviewed journals, including Cell
 and Biochemistry, and has been funded through several grants from the National
 Institutes of Health (NIH).
 
     About Cognia
     Cognia is a developer and distributor of knowledge-based products that
 facilitate the use of genomic, proteomic and cellomic/physiological
 information. Cognia provides integrated suites of high-quality, annotated
 databases, cutting edge bioinformatics tools, and associated consulting and
 training services to accelerate drug discovery and basic research. Cognia's
 products and services help pharmaceutical and biotechnology companies to
 efficiently and cost-effectively discover and develop new drugs, by
 accelerating research processes. Cognia's customers include leading
 pharmaceutical and biotechnology companies such as Schering-Plough, Eli Lilly,
 Berlex Biosciences, Scios as well as Harvard Medical School and University of
 Cincinnati.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X18659874
 
 

SOURCE Cognia Corporation
    NEW YORK, April 20 /PRNewswire Interactive News Release/ -- Cognia
 Corporation announced today the award of a one-year SBIR-Phase I grant from
 the National Institutes for General Medical Sciences (NIGMS) to create a
 comprehensive database resource on protein catabolism. The award will fund the
 initial implementation of a broadly designed system to allow access to
 relevant primary data and annotated information. The initial focus of the
 system will be the highly-regulated ubiquitin-proteasome pathways, which are
 of fundamental importance for regulating intracellular protein levels.
     This database will have direct relevance to Cognia's existing
 pharmaceutical and biotechnology customers as perturbations in the system lead
 to many types of disease, including various cancers, neurological disorders,
 and inflammatory diseases. Protein catabolism is becoming a major focus for
 drug targeting and lead identification, in addition to being of prime
 importance in the exploration of pharmaceutical side effects. "Though not
 originally described by the central dogma of biology, protein turnover has
 emerged as equal in importance to transcription," says Cognia President and
 CEO, David M. Rubin, Ph.D. "Cognia is building a system to provide biological
 context for the coming wave of proteomics data as well as standard RNA-based
 microarray data."
     Cognia is also pleased to announce that Christopher N. Larsen, Ph.D, has
 joined the team to manage the protein catabolism database product. Dr. Larsen
 has advanced the protein catabolism field through over ten years of research.
 At Emory University, he helped define the ubiquitin C-terminal hydrolase
 family, including gene members, tissue and hydrolytic specificities, and
 crystal structures. At Harvard Medical School, he elucidated subunit
 structure-function relationships of the massive eukaryotic 26S proteasome.
 Dr. Larsen's work is published in many peer-reviewed journals, including Cell
 and Biochemistry, and has been funded through several grants from the National
 Institutes of Health (NIH).
 
     About Cognia
     Cognia is a developer and distributor of knowledge-based products that
 facilitate the use of genomic, proteomic and cellomic/physiological
 information. Cognia provides integrated suites of high-quality, annotated
 databases, cutting edge bioinformatics tools, and associated consulting and
 training services to accelerate drug discovery and basic research. Cognia's
 products and services help pharmaceutical and biotechnology companies to
 efficiently and cost-effectively discover and develop new drugs, by
 accelerating research processes. Cognia's customers include leading
 pharmaceutical and biotechnology companies such as Schering-Plough, Eli Lilly,
 Berlex Biosciences, Scios as well as Harvard Medical School and University of
 Cincinnati.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X18659874
 
 SOURCE  Cognia Corporation